V esicoureteral reflux is present in one third of children presenting with fe brile urinary tract infection and has been associated with a heightened risk of renal scar ring. 1 Early randomized, controlled trials that compared antireflux surgery with antimicrobial prophylaxis showed no significant differences in the rates of recurrent urinary tract infection (re currences) and renal scarring [2] [3] [4] [5] ; however, the lack of a placebo or observation group precluded a determination that either surgery or prophylaxis was effective. More recent randomized trials, most of which were unblinded, have had con flicting results regarding the effectiveness of anti microbial prophylaxis in reducing recurrences. [6] [7] [8] [9] [10] [11] We designed the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial to determine whether longterm antimicrobial prophylaxis is effective in preventing febrile or symptomatic recurrences and reducing the likeli hood of renal scarring, and the extent to which it contributes to bacterial resistance.
Me thods

Study Design and Oversight
The study was a randomized, doubleblind, pla cebocontrolled trial of prophylaxis with tri meth oprim-sulfamethoxazole (Sulfatrim Pediatric suspension from Actavis and Sulfamethoxazole and Trimethoprim Oral Suspension from HiTech Pharmacal) in children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infection (index in fection). The project steering committee designed the trial, which was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and was conducted under an Investigational New Drug application (number 75,739) to the Food and Drug Administration. The study rationale and design have been pub lished previously, 12-16 and the protocol is avail able with the full text of this article at NEJM.org. The writing group wrote the manuscript and vouches for the completeness and accuracy of the data and analyses and the fidelity of the study to the protocol.
We enrolled children at 19 clinical sites across the United States who were 2 to 71 months of age and had grade I to IV vesicoureteral reflux. We excluded children whose index infection oc curred more than 112 days before randomization and children with coexisting urologic anomalies, contraindications for the use of trimethoprimsulfamethoxazole, or certain medical conditions (see the Supplementary Appendix, available at NEJM.org). We followed the children for 2 years to ascertain the primary outcome of febrile or symptomatic recurrence and secondary outcomes of renal scarring, failure of prophylaxis, and anti microbial resistance. We also assessed bladder and bowel dysfunction according to a standardized measure (see the Supplementary Appendix). 12, 17, 18 An NIDDK data and safety monitoring board and an institutional review board at each site approved the protocol. Parents or legal guardians of the children provided written informed con sent before enrollment.
Randomization
Randomization was performed in permuted blocks, stratified according to site. Data man agement and statistical analyses were per formed by a datacoordinating center at the University of North Carolina at Chapel Hill. We randomly assigned children to receive daily tri methoprim-sulfamethoxazole suspension (3 mg of tri meth oprim plus 15 mg of sulfamethoxa zole per kilogram of body weight) or placebo (prepared by UPM Pharmaceuticals) that was nearly identical in color, smell, taste, and con sistency. Four persons at the datacoordinating center managed the linkage of studygroup as signments with study medications; the data management software confirmed the eligibility of each child and generated assignments to coded bottles of study medication.
Study Procedures
Urine specimens from children who were not toilet trained were obtained by means of cathe terization or suprapubic aspiration; bagcollected specimens were not permitted. Clean, voided specimens were collected from toilettrained chil dren. Index and outcome infections met stringent diagnostic criteria that included evidence of pyuria on urinalysis, cultureproven infection, and fever (≥38°C) or urinary tract symptoms within 24 hours before or after urine collection. 12, 14 Renal scan ning with technetium99m-labeled dimercapto succinic acid was performed at baseline and after 1 and 2 years. Two pediatric nuclearmedicine physicians assessed the extent of renal cortical defects semiquantitatively by dividing the cortex into 12 segments and determined severity on the basis of the number of segments affected. Treat ment failure was defined as two febrile recur rences, one febrile and three symptomatic recur rences, or four symptomatic recurrences over the course of the study or as new or worsening scar ring at 1 year. 14 At baseline, after the occurrence of treatment failure, and at 24 months, we obtained rectal swabs, which were tested in a central laboratory for resistance of Escherichia coli isolates to tri meth oprim-sulfamethoxazole. 19 We also assessed, at local laboratories, resistance among pathogens identified in children with recurrences.
Statistical Analysis
We estimated that a sample of 300 children in each study group would provide at least 80% power to detect a reduction in the proportion of children with febrile or symptomatic recurrences during a 2year followup period from 20% in the placebo group to 10% in the trimethoprim-sul famethoxazole group, at a twosided alpha level of 0.05. Our a priori plan called for an intention totreat analysis of recurrences, stratified accord ing to site, with the use of a Cochran-MantelHaenszel test with missing outcomes imputed as events, as well as timetoevent analyses with the use of a stratified logrank test. We used KaplanMeier estimates to describe the proportions of children who had febrile or symptomatic recur rences or who met the criteria for treatment fail ure. We used Cox models both in analyses of treat ment effects according to age, sex, severity of reflux, and other factors and in analyses that were controlled for multiple factors. We used Fisher's exact test to compare adverse events in the two study groups. Reported P values have not been adjusted for multiple comparisons; a P value of less than 0.046 was considered to indicate sta tistical significance for the primary outcome. Sensitivity analyses of febrile or symptomatic re currences were performed, first, by including children for whom outcome data were missing and classifying them as not having had an event and, second, by omitting such children from the analyses. had bilateral reflux. Of 126 toilettrained chil dren, 71 (56.3%) had symptoms of bladder and bowel dysfunction. No significant differences in sex, race, or ethnic group were apparent between enrolled children and those who were screened but not enrolled. The study groups did not differ significantly with respect to any baseline charac teristic (Table 1) .
Adherence
Parents of 467 of the children (76.9%) reported hav ing administered the study medication at least 75% * There were no significant differences between the study groups in any of the baseline characteristics (P>0.05). UTI denotes urinary tract infection. † Race and ethnic group were reported by the parent or guardian. ‡ Four children with no insurance were classified as having public insurance. § Included in this category are children whose index infection was caused by enterococcus or pseudomonas, was not tested for susceptibility to trimethoprim-sulfamethoxazole, and was assumed to be resistant and children whose index infection was caused by bacteria that were resistant to trimethoprim but were not tested for susceptibility to sulfamethoxazole. ¶ Bladder and bowel dysfunction was defined as a score of more than 6 for toilet-trained girls and more than 9 for toilet-trained boys on a modified Dysfunctional Voiding Scoring System. 17 Scores range from 0 to 30, with higher scores indicating greater bladder and bowel dysfunction. ‖ Constipation was defined as two or more conditions according to modified criteria of the Paris Consensus on Childhood Constipation Terminology Group 18 (<3 bowel movements per week, >1 episode of fecal incontinence per week, passage of a large stool that obstructed the toilet, retentive posture and behavior, and pain during defecation). ** All 32 children had hydronephrosis of less than grade 4 on the Society for Fetal Urology scale. † † Seven children with central assessment of no vesicoureteral reflux were included in grade I, and one child with central assessment of grade V was included in grade IV (with enrollment based on local readings). Data on voiding cystourethrography for five children were missing because images were not available for central evaluation. ‡ ‡ A total of 25 children did not undergo renal scanning with technetium-99m-labeled dimercaptosuccinic acid at baseline. Among 98 children (40 in the trimethoprim-sulfamethoxazole group and 58 in the placebo group) in whom scanning was performed less than 31 days after the index UTI, scarring was identified in 1 child in the trimethoprim-sulfamethoxazole group. All other instances of scarring were identified in the 484 children (252 in the trimethoprim-sulfamethoxazole group and 232 in the placebo group) in whom scanning was performed between 31 and 112 days after the index UTI.
The of the time, and parents of 517 children (85.2%) reported having administered it at least 50% of the time. Parents of 91 children in the prophylaxis group and of 76 children in the placebo group dis continued the study medication. No significant dif ference in reported adherence to the studymedica tion regimen was noted between the study groups.
Recurrences of Febrile or Symptomatic Urinary Tract Infection
During the trial, 111 children had 171 recurrenc es of urinary tract infection ( Table 2, and Table  S1 in the Supplementary Appendix). Of 111 first recurrences, 80 (72.1%) were febrile; 2 first re currences took place after 24 months but before the study exit visit. The risk of febrile or symp tomatic recurrences was reduced by half among children who received prophylaxis as compared with those who received placebo, and the differ ence between the two groups widened progres sively over time (hazard ratio, 0.50; 95% confi dence interval [CI], 0.34 to 0.74) (Fig. 2 and 3) . The interval between enrollment and a 10% inci dence of recurrence was 336 days in the prophy laxis group and 106 days in the placebo group. Eight children (95% CI, 5 to 16) would have had * Included are 7 children (3 in the trimethoprim-sulfamethoxazole group and 4 in the placebo group) with febrile or symptomatic UTIs that occurred before a missed 2-year visit. Imputation was applied to 38 children in the trimethoprimsulfamethoxazole group and 42 children in the placebo group. † P = 0.002 by log-rank test stratified according to five core sites. ‡ Percentages are based on Kaplan-Meier 2-year estimates. § P<0.001 by the log-rank test stratified according to five core sites. ¶ Treatment failure was defined as the occurrence of two febrile UTIs (28 children), one febrile UTI and three symptomatic UTIs (2 children), four symptomatic UTIs (2 children), or new or worsening renal scarring (9 children). ‖ P = 0.04 by the log-rank test stratified according to five core sites. ** Renal scarring was defined as a decreased uptake of tracer that was associated with loss of contours or the presence of cortical thinning. † † Severe renal scarring was defined as scarring in more than 4 of 12 segments in at least one kidney or global atrophy characterized by a diffusely scarred and shrunken kidney. ‡ ‡ New renal scarring was defined as scarring on the outcome renal scan with technetium-99m-labeled dimercaptosuccinic acid that was not present at baseline. § § P<0.001 by the Cochran-Mantel-Haenszel test stratified according to five core sites. to be treated for 2 years to prevent one case of febrile or symptomatic urinary tract infection.
The New England
In our primary intentiontotreat analysis with the assumption that children with missing primaryoutcome data had had an event, a sig nificantly smaller proportion of children who received prophylaxis, as compared with those who received placebo, had a febrile or symptom atic recurrence (25.5% vs. 37.4%; relative risk, 0.68; 95% CI, 0.53 to 0.87) ( Table 2) . Similar results were obtained from sensitivity analyses that included children with missing outcome data but assumed they had not had an event (12.8% vs. 25.4%; relative risk, 0.55; 95% CI, 0.38 to 0.78) and that omitted children for whom primary outcome data were missing (14.8% vs. 27.4%; relative risk, 0.54; 95% CI, 0.38 to 0.77). The proportion of children meeting the criteria for treatment failure in the placebo group was nearly twice the proportion in the prophylaxis group (9.6% vs. 5.0%, P = 0.035). In separate Cox mod els, the studygroup effect remained unchanged after we controlled for age, whether the index urinary tract infection was the child's first or second episode, the degree of baseline reflux, and the presence or absence of baseline renal scarring (Table S2 in the Supplementary Appendix).
Renal Scarring
As reported previously, 12 a total of 98 of 582 baseline scans were obtained less than 31 days after the index infection (16.8%), and 484 were obtained between 31 and 112 days after the index infection (83.2%). A total of 21 scans (3.6%) were interpreted as indicating renal scarring, and 71 (12.2%) were interpreted as indicating acute py elonephritis. Outcome scans (at the 2year visit or 3 to 4 months after the child had met treatment failure criteria) showed no significant between group differences in the incidence of renal scar ring (11.9% in the prophylaxis group and 10.2% in the placebo group, P = 0.55), severe renal scars (4.0% and 2.6%, respectively; P = 0.37), or new re nal scars since baseline (8.2% and 8.4%, respec tively; P = 0.94) ( Table 2) .
Antimicrobial Resistance
Stool colonization with resistant E. coli was more common in the prophylaxis group than in the placebo group, but the difference was not sig nificant (Table 2) . Among 87 children with a first febrile or symptomatic recurrence with E. coli, the proportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% with prophylaxis and 19% with placebo (P<0.001).
Effect Modifiers
Children with grade III or IV reflux at baseline were more likely to have febrile or symptomatic recurrences than were children with grade I or II reflux (64 of 280 children [22.9%] vs. 46 of 322 [14.3%], P = 0.003). Hazard ratios for recurrences consistently favored the prophylaxis group, irre spective of sex, age at study entry, degree of re flux, whether children had one or two urinary tract infections before enrollment, whether the index infection was caused by a resistant patho gen, and whether reflux present at baseline had resolved, improved, not changed, or worsened at 2 years (Fig. 3 ). There were significant interac tions between study group and the type of index infection (P = 0.04) and between study group and the presence or absence of bladder and bowel dysfunction at baseline (P = 0.02). The estimated hazard ratio for a febrile or symptomatic recur rence in the prophylaxis group relative to the pla cebo group was 0.41 (95% CI, 0.26 to 0.64) among children with a febrile index infection and 1.28 (95% CI, 0.47 to 3.46) among children with a nonfebrile index infection. Corresponding hazard ratios for children with and those without bladder and bowel dysfunction at baseline were 0.21 (95% CI, 0.08 to 0.58) and 1.40 (95% CI, 0.43 Shown are Kaplan-Meier estimates of the cumulative percentage of children who had a recurrent febrile or symptomatic UTI according to study group. Fewer children assigned to TMP-SMX prophylaxis had a UTI than children assigned to placebo (P<0.001 by log-rank test). I bars indicate 95% confidence intervals.
The to 4.58). The study population included too few boys to evaluate the effect of circumcision, but all four boys with a first recurrence were uncir cumcised at baseline.
Reflux Status at 2 Years
Voiding cystourethrography was performed at 2 years in 428 children. Reflux was considered to be resolved in 218 children (50.9%), improved in 100 (23.4%), unchanged in 79 (18.5%), and worse in 31 (7.2%).
Adverse Events
We found no significant betweengroup differ ences in the proportions of children with fever (14.2% in the prophylaxis group and 18.0% in the placebo group, P = 0.23), otitis media (4.3% and 7.9%, respectively; P = 0.09), diarrhea (3.6% and 6.2%, P = 0.19), pharyngitis (6.3% and 4.6%, P = 0.38), rash (7.6% and 7.5%, P = 1.0), or viral infection (4.6% and 5.2%, P = 0.85) ( Depicted are hazard ratios (rectangles) and 95% confidence intervals (horizontal lines) for a first recurrent febrile or symptomatic UTI overall and for subgroups. P values are based on Wald tests for the interaction of subgroup with study-group assignment. Hazard ratios of less than 1.00 indicate that the risk of a recurrent febrile or symptomatic UTI was lower among the children randomly assigned to antimicrobial prophylaxis than among those assigned to placebo. BBD denotes bladder and bowel dysfunction.
The nificantly between the prophylaxis and placebo groups (41.1% and 48.5%, respectively; P = 0.06) ( Table S4 in the Supplementary Appendix).
Discussion
Antimicrobial prophylaxis in children with vesi coureteral reflux diagnosed after a first or sec ond urinary tract infection was associated with a halving of the risk of febrile or symptomatic re currences. Differences between the prophylaxis and placebo groups were apparent early on and increased over a 2year period. Children with blad der and bowel dysfunction at baseline and chil dren whose index infection was febrile derived particular benefit from prophylaxis, with reduc tions in recurrences of approximately 80% and 60%, respectively. Rates of renal scarring at the outcome visit were low and were not reduced by prophylaxis, perhaps because most children were enrolled after their first infection and because parents, who were instructed to be vigilant, sought early medical attention. Not unexpectedly, recurrences that did occur in children who re ceived prophylaxis were more likely to have been caused by a resistant pathogen. We designed our trial to avoid certain limita tions of previous studies. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 20 We enrolled, from a variety of clinical settings, a large, representa tive sample of children with vesicoureteral reflux (grade I to IV) that was diagnosed after a uri nary tract infection. We applied stringent diag nostic criteria and used standardized scales to identify predisposing factors. 12 Our radiologists applied standardized criteria to enhance the reli ability of their interpretations of urinary tract images. 15, 16 Our trial has certain limitations: our results may not be applicable to children with different demographic or clinical characteristics or children in locales where the choice of tri meth oprim-sulfamethoxazole may be limited by susceptibility patterns or clinical acceptability, and some of our subgroup analyses had limited statistical power.
There are both similarities and differences between our findings and those of two other trials. 10, 20 Craig et al. enrolled 576 Australian children under the age of 18 years with stringent ly defined urinary tract infection in a placebo controlled trial of trimethoprim-sulfamethoxa zole prophylaxis. 10 Sixtyfour percent of the children were girls. Twelve months of prophy laxis was associated with a reduction in the ab solute risk of symptomatic recurrences of 6 per centage points (number needed to treat, 14). However, pyuria was not found at the index in fection in 32% of the children, only 42% of the children had reflux, 41% had normal voiding studies, 17% did not undergo voiding cystoure thrography, and renal scanning with technetium 99m-labeled dimercaptosuccinic acid was per formed after 1 year in only 27% of the children. In our trial, all children were younger than 6 years of age, 92% were girls, all were considered to have grade I to IV reflux, the diagnosis of infec tion required the presence of pyuria, renal scan ning was performed after 2 years in 76% of the children, and the effect of prophylaxis was sus tained over a 2year period (number needed to treat, 8).
Brandström et al. randomly assigned 203 Swedish children 12 to 23 months of age with grade III or IV reflux to receive antimicrobial prophylaxis (with trimethoprim, nitrofurantoin, or cefadroxil), endoscopic treatment, or surveil lance only. 20 A total of 37% of the participants were boys, most of whom were uncircumcised. Clinicians and parents were aware of the study group assignments, and bagcollected urine spec imens were permitted. Significant differences in outcome were noted only in girls. Girls in the surveillanceonly group had the highest incidence of febrile recurrence and the shortest time to a first recurrence; girls who received antimicrobial prophylaxis had the lowest incidence of renal scarring at 2 years of followup. 21 Do our results support recent recommenda tions regarding urinary tract imaging in children with a first febrile urinary tract infection? 22 Many factors may influence that decision in in dividual children, including the presence or ab sence of a family history of vesicoureteral reflux, age, sex, and race, which affect the probability that vesicoureteral reflux is present; the severity of the clinical course of the infection; the status of bladder and bowel function; the cost of void ing cystourethrography and associated discom fort; the importance that parents place on pre venting recurrences (which sometimes result in alarming symptoms, hospitalization, and paren tal work loss and which may influence the deci sion to proceed to surgery in children found to have reflux); perceived parental ability to adhere to a prophylaxis regimen; parental concern about potential longterm effects of prophylaxis, such as the development of antimicrobial resistance and alterations of the microbiome; and most im portant, the effectiveness of prophylaxis in pre venting recurrences. As long as evidence supporting the benefit of prophylaxis was dubious, the recommendation of a watchfulwaiting approach, without perfor mance of a voiding cystourethrographic study, 22 seemed reasonable, because the imaging find ings would not affect the nature of treatment. However, our finding that antimicrobial prophy laxis was associated with a reduced risk of re currence may warrant reconsideration of that recommendation. Decision analysis and cost effectiveness analysis may help to clarify the clinical and financial tradeoffs, which may help clinicians and families reach more informed deci sions about the advisability of imaging in young children such as those in our study.
